1248 Management LLC Makes New Investment in Sanofi $SNY

Key Points

• 1248 Management LLC purchased 9,344 shares of Sanofi, valued at approximately $518,000, during the 1st quarter.
• Multiple analysts upgraded Sanofi's stock rating, with Barclays and JPMorgan Chase giving it an "overweight" and "buy" rating, respectively.
• Sanofi reported a net margin of 21.47% for its last quarter, generating $11.34 billion in revenue but missing EPS estimates by $0.06.

1248 Management LLC purchased a new stake in Sanofi (NASDAQ:SNY - Free Report) in the 1st quarter, according to its most recent filing with the SEC. The institutional investor purchased 9,344 shares of the company's stock, valued at approximately $518,000.

Other large investors have also recently added to or reduced their stakes in the company. Accent Capital Management LLC acquired a new stake in Sanofi in the 1st quarter valued at $29,000. Eastern Bank increased its holdings in Sanofi by 121.0% in the 1st quarter. Eastern Bank now owns 548 shares of the company's stock valued at $30,000 after purchasing an additional 300 shares in the last quarter. Golden State Wealth Management LLC increased its holdings in Sanofi by 619.3% in the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock valued at $35,000 after purchasing an additional 545 shares in the last quarter. Banque Transatlantique SA acquired a new stake in Sanofi in the 1st quarter valued at $33,000. Finally, Brentview Investment Management LLC acquired a new stake in Sanofi in the 1st quarter valued at $42,000. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Down 1.3%

Shares of SNY stock traded down $0.62 during trading hours on Friday, hitting $47.03. 2,728,115 shares of the company were exchanged, compared to its average volume of 2,686,205. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. Sanofi has a one year low of $44.73 and a one year high of $60.12. The business's 50-day simple moving average is $48.64 and its two-hundred day simple moving average is $51.11. The stock has a market capitalization of $115.48 billion, a price-to-earnings ratio of 11.31, a P/E/G ratio of 1.12 and a beta of 0.51.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The company had revenue of $11.34 billion for the quarter, compared to the consensus estimate of $9.91 billion. During the same period in the previous year, the business posted $1.73 EPS. The business's revenue for the quarter was down 7.0% on a year-over-year basis. Sell-side analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on SNY. Guggenheim restated a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. JPMorgan Chase & Co. upgraded Sanofi from a "neutral" rating to an "overweight" rating in a research note on Friday, August 8th. Barclays restated an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Wall Street Zen upgraded Sanofi from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "hold" rating to a "buy" rating in a research note on Tuesday, September 2nd. Three analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, Sanofi has an average rating of "Buy" and an average target price of $62.67.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.